PRESS RELEASE

Shortcuts 2024 2023 2022 2021 2020 2019

2024

• BioCardia Regains Full Compliance with Nasdaq Listing Requirements

• BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

• BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

• BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

• FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

• BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

• BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

• BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

• Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

• BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

• CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

• BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

• BioCardia Announces Reverse Stock Split

• BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

• BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

• BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

• BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

• BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

• BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

• BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

• BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

• BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

• BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

• BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

• BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

2023

• BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

• BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

• BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

• BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

• BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

• BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

• BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

• BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

• BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

• BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

• BioCardia Reports Second Quarter 2023 Business Highlights And Financial Results

• BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023

• BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

• BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency

• BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study

• BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan

• BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

• BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

• BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

• BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

• BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

• BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

• BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

• BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

• Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

• BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

2022

• BioCardia Letter to Shareholders

• BioCardia Announces $3.6 Million Private Placement of Common Stock

• BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

• BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

• BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

• BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

• CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting

• BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

• BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines Conference

• BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

• BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure

• BioCardia Reports Second Quarter 2022 Business Highlights and Financial Results

• BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

• BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

• BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

• BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies

• BioCardia Reports First Quarter 2022 Business Highlights and Financial Results

• BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

• BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

• BioCardia Reports 2021 Financial Results and Recent Business Highlights

• BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022

• BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure

• BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

• BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

• BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

• BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference

2021

• BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates

• BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

• BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021

• BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

• BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies

• BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial

• BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)

• CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021

• BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

• BioCardia to Participate in Upcoming Investor Conferences

• BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

• BioCardia to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021

• BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies

• BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

• BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021

• BioCardia Announces European Patent Office Decision to Grant Patent on Autologous Cell Therapy Patient Selection Diagnostic Assay

• BioCardia to Be Added to the Russell Microcap® Index

• BioCardia to Present at the LD Micro Virtual Invitational Conference on June 8, 2021

• BioCardia Reports First Quarter 2021 Financial Results and Business Highlights

• BioCardia Signs Agreement with Leading Japanese Biotechnology Company for Catheter Biotherapeutic Delivery Product Candidates

• BioCardia Reports 2020 Financial Results and Recent Business Highlights

• BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

• BioCardia Signs Agreement with Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates

• BioCardia Announces Clinical Leadership Changes

• BioCardia Update on Cell Therapy Product Development and 2021

• Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors

2020

• BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies

• BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed

• BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The Market Under NASDAQ Rules

• BioCardia Anticipates DSMB Feedback on Interim Data from Pivotal Phase 3 CardiAMP Heart Failure Trial

• BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

• BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used In CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems

• BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights

• Published Peer-Reviewed Initial Data From BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function

• BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery

• BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

• BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights

• BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020

• BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia

• BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

• BioCardia Announces Pricing of $10.0 Million Public Offering

• BioCardia Reports First Quarter 2020 Financial Results and Business Highlights

• BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure

• BioCardia Announces FDA-Recommended Modifications to Primary Endpoint for CardiAMP Cell Therapy Heart Failure Trial to Support Marketing Approval

• BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart

• BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia, Inc.

• BioCardia Reports 2019 Financial Results and Recent Business Highlights

• BioCardia Announces Positive DSMB Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study, As Planned

• BioCardia Announces Timing For Prespecified Data Safety Monitoring Board Report on Pivotal CardiAMP Heart Failure Trial

• BioCardia Announces FDA Clearance of Morph DNA Deflectable Guide Catheter

• BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery

2019

• BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights

• BioCardia to Present at Dawson James Securities' 5th Annual Small Cap Growth Conference

• BioCardia Receives CE Mark Renewal for Helix Biotherapeutic Delivery Catheter and Morph Guide Catheter Through May 2024

• BioCardia Announces the Appointment of Two New Board Members

• BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures

• BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned

• BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights

• BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery

• BioCardia Announces Closing of $10.0 Million Public Offering

• BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to NASDAQ

• BioCardia Signs Exclusive Development Agreement with AstraZeneca

• BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery

• BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange

• Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia's Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

• Biocardia Reports 2019 First Quarter Financial Results and Business Highlights

• BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transeptal Access to Heart

• BioCardia Reports 2018 Financial Results and Recent Business Highlights